Napredna pretraga

Pregled bibliografske jedinice broj: 316303

Hypereosinophilic syndrome: diagnosis and treatment


Peroš-Golubičić, Tatjana; Smojver-Ježek, Silvana
Hypereosinophilic syndrome: diagnosis and treatment // Current Opinion in Pulmonary Medicine, 13 (2007), 5; 422-427 (međunarodna recenzija, pregledni rad, znanstveni)


Naslov
Hypereosinophilic syndrome: diagnosis and treatment

Autori
Peroš-Golubičić, Tatjana ; Smojver-Ježek, Silvana

Izvornik
Current Opinion in Pulmonary Medicine (1070-5287) 13 (2007), 5; 422-427

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
Hypereosinophilic syndrome; tyrosine kinase inhibitors

Sažetak
Purpose of review: Hypereosinophilic syndrome is increasingly recognized as a heterogeneous group of disorders, in some cases with precisely defined pathogenesis, which has led to changes in diagnostic approaches and therapeutic strategies. An update on causes and modern therapy is presented here. Recent findings: Clonal eosinophilias belong to the group of myeloid malignancies. Karyotypically occult FIP1L1- platelet-derived growth factor receptor alpha and beta rearranged eosinophilic disorders respond to imatinib mesylate with almost 100% efficacy. If standard therapies fail, the FIP1L1- platelet-derived growth factor receptor-negative cases of hypereosinophilic syndrome should also be considered for treatment with imatinib. The recognition of acquired resistance to imatinib has aroused interest in developing new tyrosine kinase inhibitors. Other subgroups of clonal eosinophilias have been molecularly defined, but the curative verification of pathogenetic relevance has not been certified. Hypereosinophilic syndrome patients with abnormal T-cell populations have benefited from treatment with anti IL-5 monoclonal antibodies. SUMMARY: The FIP1L1- platelet-derived growth factor receptor alpha and beta-positive patients, and those with abnormal T-cell populations are currently the only clearly defined treatable subgroups of hypereosinophilic syndrome. The FIP1L1- platelet-derived growth factor receptor alpha-negative responders to imatinib pose a question as to the existence of subentities with unrecognized tyrosine kinases-based mutation. The search for such cases and other treatable subgroups of hypereosinophilic syndrome has already begun.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekt / tema
0144002

Ustanove
Klinika za plućne bolesti "Jordanovac"

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Uključenost u ostale bibliografske baze podataka:


  • Excerpta Medica
  • Index Medicus